Skip to main content
. Author manuscript; available in PMC: 2023 Apr 14.
Published in final edited form as: Clin Cancer Res. 2022 Oct 14;28(20):4444–4455. doi: 10.1158/1078-0432.CCR-22-1221

Figure 1. Target specificity and activity profile for ten PI3Ki.

Figure 1.

The activity of buparlisib, compound 7n, copanlisib, duvelisib, idelalisib, nemiralisib, pictilisib, pilaralisib, umbralisib, and ZSTK474 were profiled at 1 μM over a panel of up to 468 human kinases, including atypical, mutant, lipid, and pathogen kinases (lower dendrograms), using the DiscoveRx kinase assays. The upper dendrograms show (moving clockwise from the upper, purple section) tyrosine kinases (TK), tyrosine kinase-like kinases (TKL), STE protein kinases (STE), casein kinase 1 family (CK1), protein kinase A, G, and C families (AGC), Ca2+/calmodulin-dependent kinases (CAMK), CMGC kinase group (CMGC), and other. The size of the circles represents the percentage of target inhibition, with larger circles indicating a stronger inhibition compared with control, as defined in the scale.